Jiangsu Key Laboratory of Neuropsychiatric Diseases and Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou, Jiangsu 215123, China
Auto-generated profile, based on publicly available information
Feng Liu
Jiangsu Key Laboratory of Neuropsychiatric Diseases and Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou, Jiangsu 215123, China
A mild and transition-metal-free protocol is herein presented for chloro-, bromo- and trifluoromethylthiotrifluoromethylation of unactivated alkenes. The easy-handling Langlois reagent, as well as N-halophthalimide and N-trifluoromethylthiosaccharin, is used in this method. In the presence of an organic photoredox catalyst N-methyl-9-mesityl acridinium, a broad range of desired products were afforded in satisfactory yields upon visible-light irradiation via a radical process.
A redox-neutral, mild, and simple protocol is developed for the synthesis of α-trifluoromethylated ketones from vinyl azides under transition-metal-free conditions. In the presence of organic photoredox catalyst N-methyl-9-mesityl acridinium and sodium trifluoromethanesulfinate, a broad range of substituted vinyl azides were found to react smoothly upon visible-light irradiation, readily furnishing the corresponding products in satisfied yields.
A visible-light-mediated radical allylation of primary amine-derived Katritzky salts with allylic sulfones via C(sp3)–N bond activation is reported, furnishing the corresponding alkenes in satisfactory yields. This mild protocol provides an efficient strategy for site-specific C(sp3)–C(sp3) bond formation using abundant feedstock primary amines, particularly α-amino acids as alkyl radical precursors. This photocatalytic reaction demonstrates a broad substrate scope and good functional group tolerance.
29 December 2016 in Expert Opinion on Therapeutic Patents
Introduction: Since the first pan-HDAC inhibitor SAHA was approved by U.S. FDA 10 years ago, HDACs including SIRT1-7 have received significant attention due to the fact that aberrant histone deacetylase activtiy has been implicated in a variety of human diseases, such as cancers, virus infection, and neurodegenerative diseases. During the past years, a considerable achievement of development of isoform- or class-selective HDAC inhibitors has been made, yielding many drug candidates for further clinical studies, which represents a state-of-the-art technology in the drug discovery arena. Areas covered: This review covers new patents and articles about isoform- or class-selective HDAC inhibitors during the last four years, as well as the therapeutic potential of these compounds. Expert opinion: HDACs represent one of the most promising therapeutic targets, particularly for tumor therapy though their roles in cancer are still blurry. From 2012 to present, along with the advances of structural biology and homology models, lots of isoform- or class-selective HDAC inhibitors, such as hydroxamic acids and benzamides with various capping groups were found, providing a promising way to circumvent drug toxicity and side-effect issues, as well as providing chemical probes for further better understanding of the biological process related to specific isoform.
The radical tri-/difluoromethylation of para-quinone methides with readily available sodium tri-/difluoromethanesulfinate via organic photoredox catalysis is described. This reaction is external oxidant free and exhibits wide functional group compatibility, providing the desired products in useful yields. However, the reaction of para-quinone methides with CH2FSO2Na and CH3SO2Na under the optimal conditions gives the nucleophilic conjugate addition products. The results indicate that the strong inductive effect of the fluorine atom may play a critical role in the reactivity of the sodium sulfinates.